Subcutaneous amivantamab demonstrated robust activity in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with checkpoint inhibitors and platinum chemotherapy.
Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
Advertisement
Articles by Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
3
FDA Approves Gazyva for Active Lupus Nephritis
4
Turning the Tide in TNBC: Trop2-Targeted Therapies Improve Patient Outcomes
5
